Integrative Cancer Scholars Training Grant

综合癌症学者培训补助金

基本信息

  • 批准号:
    10680574
  • 负责人:
  • 金额:
    $ 26.36万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1983
  • 资助国家:
    美国
  • 起止时间:
    1983-09-01 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

Abstract Our goal is to recruit, train and develop the next generation of leaders in cancer research. To achieve this objective, we will implement the Integrative Cancer Scholars (ICS) program as described in this competitive renewal of our long-standing Cancer Biology Training Program. ICS is an innovative predoctoral and postdoctoral fellows training program that embraces a paired-mentor team approach to maximize the impact and significance of cancer research. Specifically, Scholars choose one basic science mentor and one clinical science mentor from among nationally competitive basic and physician scientists. From the mentor pair, the Scholar selects a `lead' mentor from among the faculty with well-funded collaborative research programs with a broad range of cancer research specialties: Genomic and Epigenetic Instability, Tumor Microenvironment, Cancer Prevention and Control, Developmental Therapeutics, Cancer Imaging, Tumor Viruses and Immunology, Tumor Progression and Metastasis, and Cancer Pain. ICS is a unique program with distinct training events designed to integrate current molecular and clinical cancer concepts. Each Scholar is expected to conduct original cutting-edge research under the guidance of the mentor-pair and to participate in clinical cases with their chosen physician mentor. Progress of each trainee is ensured through compulsory committee meetings and annual evaluations by the mentor-pair. Scholars also participate in career development and national networking opportunities, including hosting thought leaders in our Cancer Biology Seminar Series, acquiring new targeted skills in educational workshops, and community engagement with oncologists and biotechnology experts. Additionally, Scholars are provided support to travel and present their work at a national meeting. ICS is associated with the Cancer Biology Graduate Interdisciplinary Program which provides instruction in cancer causation, epidemiology, prevention, and grant writing through specific coursework and a symposium featuring presentations of pre- and postdoctoral research. The postdoctoral training plan ensures that each trainee navigates a path of comprehensive training, leading to a mature scholarship and ability to conduct independent, cutting-edge research. The program is designed to expose each trainee to the range of current thought in the cancer field, to teach state-of-the-art laboratory techniques, to emphasize critical thinking skills, to introduce real-world aspects of clinical work, and to refine their career-development skills, particularly in networking, communication and grant/manuscript preparation. Pre- and postdoctoral researchers from laboratories of the participating mentors are eligible for ICS support, and Scholars are selected through a competitive process. Support from the UA, state-of-the-art research core facilities, and opportunities for underrepresented-minority researchers (UA is top of all Research I institutions for URMs in graduate school) round out a rich environment for training the future leaders of cancer research.
抽象的 我们的目标是招募、培训和培养下一代癌症研究领导者。为了实现这一目标 为了实现这一目标,我们将实施本竞赛中所述的综合癌症学者 (ICS) 计划 更新我们长期的癌症生物学培训计划。 ICS是一个创新的博士前和 博士后研究员培训计划采用结对导师团队方法,以最大限度地发挥影响 以及癌症研究的意义。具体来说,学者们选择一名基础科学导师和一名临床导师 来自全国有竞争力的基础科学家和医师科学家的科学导师。从导师对来看, 学者从拥有资金充足的合作研究项目的教师中选择一位“首席”导师 广泛的癌症研究专业:基因组和表观遗传不稳定性、肿瘤微环境、 癌症预防和控制、发育治疗、癌症成像、肿瘤病毒和 免疫学、肿瘤进展和转移以及癌痛。 ICS 是一个独特的项目,具有独特的 旨在整合当前分子和临床癌症概念的培训活动。每个学者都被期待 在导师对的指导下进行原创前沿研究并参与临床 与他们选择的医生导师一起处理病例。通过强制委员会确保每位学员的进步 导师对的会议和年度评估。学者还参与职业发展和 全国交流机会,包括在我们的癌症生物学研讨会系列中接待思想领袖, 在教育研讨会以及与肿瘤学家和社区的参与中获得新的有针对性的技能 生物技术专家。此外,还为学者提供旅行和在国家级会议上展示其工作的支持 会议。 ICS 与癌症生物学研究生跨学科项目相关,该项目提供 通过特定的课程和研究,提供癌症因果关系、流行病学、预防和拨款写作方面的指导 研讨会以博士前和博士后研究的介绍为特色。博士后培养计划保证 每个学员都走一条全面的培训之路,从而获得成熟的奖学金和能力 进行独立的前沿研究。该计划旨在让每位学员接触到一系列 癌症领域的当前思想,教授最先进的实验室技术,强调批判性思维 技能,介绍临床工作的现实方面,并提高他们的职业发展技能,特别是 在网络、沟通和资助/手稿准备方面。博士前和博士后研究人员 参与导师的实验室有资格获得 ICS 支持,并且学者是通过 竞争过程。 UA 的支持、最先进的研究核心设施以及机会 代表性不足的少数族裔研究人员(UA 在研究生院 URM 的所有研究 I 机构中名列前茅) 为培训癌症研究的未来领导者提供丰富的环境。

项目成果

期刊论文数量(69)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Determination of spirogermanium (2-aza-8-germanspiro[4.5]-decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride) by fluorometric ion-pair extraction. Application to the uniformity of content of solutions for intravenous injection.
通过荧光离子对萃取法测定螺锗(2-氮杂-8-germanspiro[4.5]-癸烷-2-丙胺-8,8-二乙基-N,N-二甲基二氯)。
Expression of beta-actin during progression of mouse skin tumors.
小鼠皮肤肿瘤进展过程中β-肌动蛋白的表达。
  • DOI:
    10.1093/carcin/10.8.1439
  • 发表时间:
    1989
  • 期刊:
  • 影响因子:
    4.7
  • 作者:
    Ostrowski,LE;Krieg,P;Finch,J;Cress,AE;Nagle,RB;Bowden,GT
  • 通讯作者:
    Bowden,GT
Expression of the EVI1 gene in chronic myelogenous leukemia in blast crisis.
EVI1基因在慢性粒细胞白血病急变期的表达。
  • DOI:
  • 发表时间:
    1993
  • 期刊:
  • 影响因子:
    11.4
  • 作者:
    Russell,M;Thompson,F;Spier,C;Taetle,R
  • 通讯作者:
    Taetle,R
B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro.
B7-1 可在体内增强对分泌白细胞介素 2 的肿瘤疫苗的反应,但无法在体外诱导幼稚细胞的反应。
  • DOI:
    10.1089/hum.1995.6.10-1299
  • 发表时间:
    1995
  • 期刊:
  • 影响因子:
    4.2
  • 作者:
    Salvadori,S;Gansbacher,B;Wernick,I;Tirelli,S;Zier,K
  • 通讯作者:
    Zier,K
A DNA polymerase alpha-associated 56 kDa protein kinase.
一种 DNA 聚合酶 α 相关的 56 kDa 蛋白激酶。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jennifer S Carew其他文献

Jennifer S Carew的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jennifer S Carew', 18)}}的其他基金

Targeting Lysosomal Vulnerabilities in Renal Pathogenesis
针对肾脏发病机制中的溶酶体脆弱性
  • 批准号:
    10570295
  • 财政年份:
    2022
  • 资助金额:
    $ 26.36万
  • 项目类别:
Development of lysosome targeted therapeutics
溶酶体靶向治疗药物的开发
  • 批准号:
    10482643
  • 财政年份:
    2022
  • 资助金额:
    $ 26.36万
  • 项目类别:
Targeting NEDD8-Mediated Protein Turnover in AML
在 AML 中靶向 NEDD8 介导的蛋白质周转
  • 批准号:
    8632457
  • 财政年份:
    2014
  • 资助金额:
    $ 26.36万
  • 项目类别:
Targeting NEDD8-Mediated Protein Turnover in AML
在 AML 中靶向 NEDD8 介导的蛋白质周转
  • 批准号:
    8845524
  • 财政年份:
    2014
  • 资助金额:
    $ 26.36万
  • 项目类别:
Targeting NEDD8-Mediated Protein Turnover in AML
在 AML 中靶向 NEDD8 介导的蛋白质周转
  • 批准号:
    9310390
  • 财政年份:
    2014
  • 资助金额:
    $ 26.36万
  • 项目类别:

相似海外基金

Molecular Epidemiological and pathological studies on the association between lipoprotein(a) and malignant neoplasms
脂蛋白(a)与恶性肿瘤关系的分子流行病学及病理学研究
  • 批准号:
    17K08718
  • 财政年份:
    2017
  • 资助金额:
    $ 26.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Integrated analysis and detection of new therapeutic target aimed for improvement of prognosis in the patients with pancreatic malignant neoplasms
综合分析检测改善胰腺恶性肿瘤患者预后的新治疗靶点
  • 批准号:
    24501337
  • 财政年份:
    2012
  • 资助金额:
    $ 26.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
GENETIC PREDISPOSITION TO SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD
儿童期后第二次恶性肿瘤的遗传倾向
  • 批准号:
    6116914
  • 财政年份:
    1998
  • 资助金额:
    $ 26.36万
  • 项目类别:
GENETIC PREDISPOSITION TO SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD
儿童期后第二次恶性肿瘤的遗传倾向
  • 批准号:
    6219852
  • 财政年份:
    1998
  • 资助金额:
    $ 26.36万
  • 项目类别:
GENETIC PREDISPOSITION TO SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD
儿童期后第二次恶性肿瘤的遗传倾向
  • 批准号:
    6278109
  • 财政年份:
    1997
  • 资助金额:
    $ 26.36万
  • 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
  • 批准号:
    2305338
  • 财政年份:
    1996
  • 资助金额:
    $ 26.36万
  • 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
  • 批准号:
    2305324
  • 财政年份:
    1996
  • 资助金额:
    $ 26.36万
  • 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
  • 批准号:
    2451660
  • 财政年份:
    1996
  • 资助金额:
    $ 26.36万
  • 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
  • 批准号:
    2451659
  • 财政年份:
    1996
  • 资助金额:
    $ 26.36万
  • 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
  • 批准号:
    2305309
  • 财政年份:
    1995
  • 资助金额:
    $ 26.36万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了